Why is levosimendan's FDA path in the U.S. still narrow?

Levosimendan reportedly stumbled again in a U.S. phase 3 trial, adding to a history that already included a failed FDA approval bid decades ago. The article says Tenax is still pursuing a narrow FDA route, meaning approvability may now depend more on a tightly argued regulatory case than on clearly decisive efficacy data.